Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RHOA | P61586 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | USP8 | P40818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265934 | 0.66 | CYP3A4 (0.40) | ALDH1A1PTPRCMEN1KMT2ACYP3A4 | |
| SCHEMBL887290 | 0.64 | MAOA (0.37) | ALDH1A1PTPRCMEN1KMT2ANPSR1 | |
| Anthraquinone SCHEMBL10663875 | 0.61 | PTPRC (0.56) | ALDH1A1PTPRCMEN1KMT2ACYP3A4 | |
| SCHEMBL7154549 | 0.59 | ALDH1A1 (0.38) | ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL16163130 | 0.58 | LMNA (0.43) | ALDH1A1MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL7764770 | 0.58 | HPGD (0.55) | ALDH1A1PTPRCCYP3A4TSHRHSD17B10 | |
| SCHEMBL8678648 | 0.57 | ALDH1A1 (0.49) | ALDH1A1PTPRCMEN1KMT2ACYP3A4 | |
| SCHEMBL30767916 | 0.57 | ALDH1A1 (1.00) | ALDH1A1PTPRCMEN1KMT2ANPSR1 | |
| SCHEMBL1715729 | 0.57 | ALDH1A1 (1.00) | ALDH1A1PTPRCMEN1KMT2ANPSR1 | |
| SCHEMBL24206010 | 0.56 | MEN1 (0.32) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | ALDH1A1 1001/4885PTPRC 4452/4885MEN1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.